FDA Approves Olaparib for Frontline Maintenance Therapy for Ovarian Cancer
The Federal Drug Administration (FDA) made an exciting announcement this week with the first approval for PARP inhibitors to be used for patients following their initial diagnosis and treatment to reduce the risk of recurrence. The FDA approved the use